After the 3rd cycle, the prevalence of hyperglycemia in patients with colon cancer, in patients treated with 5FU, in patients treated with FOLFOX regimen were higher than in patients with breast cancer, in patients treated with cyclophosphamid, in patients treated with AC regimen, with respectively statistically significant differences (OR: 2.31; 95% CI: 1.39 - 3.87; p<0.01); (OR: 2.15; 95% CI: 1.28 - 3.61; p<0.01); (OR: 2.06; 95% CI: 1.21 - 3.48; p<0.01).